Advertisement

Radiation Therapy of Melanomas

  • Renato G. Panizzon

Abstract

Although surgery is by far the most common form of treatment for most cutaneous melanomas, there are some limited indications for radiation therapy. Irradiation has a definitive role in the treatment of lentigo maligna (LM), especially with grenz rays. For lentigo maligna melanomas (LMM), more penetrating soft x rays show great promise as a curative treatment modality.1–3 Therapeutic trials with radiotherapy of inoperable nonlentiginous melanomas and of metastatic lesions to skin or lymph nodes have shown that these lesions are less responsive to ionizing radiation. The results of numerous clinical investigations favor techniques that utilize high doses per fraction (the term “high dose” fraction is used in this connection, in contrast to the low standard 200-cGy fractions used in radiation oncology). In patients treated with curative intent, either definitively or adjunctively, the difference between high-dose fractions and low- dose fractions may be decisive. More prospective trials are needed to test the reported greater efficacy of high doses. Late complications associated with high dose per fraction irradiation are not a relevant risk in patients with metastatic melanoma where survival is generally limited. The use of high doses per fraction is not really new; radiotherapy of melanoma has a long tradition in our institution since Miescher first introduced it several decades ago.3

Keywords

Melanoma Cell Dose Recommendation Cutaneous Melanoma Nodular Melanoma Superficial Spreading Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooper JS. Radiotherapy of malignant melanoma. Dermatol Clin. 1985; 3: 341–350.PubMedGoogle Scholar
  2. 2.
    Goldschmidt H. Ionizing radiation therapy. In: Domonkos AN, Arnold HL, Odom RB, eds. Andrew’s Diseases of the Skin. Philadelphia, Penn: WB Saunders; 1990.Google Scholar
  3. 3.
    Panizzon R. Die Radiotherapie des malignen Melanoms der Haut-eine Renaissance? Hautarzt. 1986; 37: 481–484.PubMedGoogle Scholar
  4. 4.
    Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971; 31: 830–833.PubMedGoogle Scholar
  5. 5.
    Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1971; 44: 816–817.PubMedCrossRefGoogle Scholar
  6. 6.
    Wheldon TE. Optimal fractionation for the radiotherapy of tumor cells possessing wide-shouldered survival curves. Br J Radiol. 1979; 52: 417–418.PubMedCrossRefGoogle Scholar
  7. 7.
    Rofstad EK, Brustad T. Broad-shouldered survival curves of a human melanoma xenograft. Acta Radiol (Oncol). 1981; 20: 261–265.CrossRefGoogle Scholar
  8. 8.
    Pourreau-Schneider N, Malaise EP. Relationship between surviving fractions using the colony method, the LD 50, and the growth delay after irradiation of human melanoma cells grown as multicellular spheroids. Radiat Res. 1981; 85: 321–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Sutherland RM, Inch WR, McCredie JA, et al. A multi-component radiation survival curve using an in vitro tumour model. Int J Radiat Biol. 1970; 18: 491–495.CrossRefGoogle Scholar
  10. 10.
    Yuhas JM, Blake S, Weichselbaum RR. Quantitation of the response of human tumour spheroids to daily radiation exposures. Int J Radiat Oncol Biol Phys. 1984; 10: 2323–2327.PubMedCrossRefGoogle Scholar
  11. 11.
    von Rottkay P. Strahlentherapie bei Malignen Melanomen mit akzelerierter Fraktionierung. Strahlenther Onkol. 1987; 163: 139–143.Google Scholar
  12. 12.
    Klausner JM, Gutman M, Rozin RR, et al. Conventional fractionation radiotherapy combined with 5-fluorouracil for metastatic malignant melanoma. Am J Clin Oncol. 1987; 10: 448–450.PubMedCrossRefGoogle Scholar
  13. 13.
    Dische S. Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma. Radiother Oncol. 1987; 10: 111–116.PubMedCrossRefGoogle Scholar
  14. 14.
    Arcangeli G, Benassi M, Cividalli A, et al. Radiotherapy and hyperthermia. Cancer. 1987; 60: 950–956.PubMedCrossRefGoogle Scholar
  15. 15.
    Mameghan H, Knittel T. Response of melanoma to heat and radiation therapy. Med J Aust. 1988; 149: 474–481.PubMedGoogle Scholar
  16. 16.
    Mishima Y, Ichihashi M, Tsuji M, et al. Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound. J Invest Dermatol. 1989; 92 (suppl): 321s–325s.Google Scholar
  17. 17.
    Sealy R, Hockly J, Shepstone B. The treatment of malignant melanoma with cobalt and hyperbaric oxygen. Clin Radiol. 1974; 25: 211 - 215.PubMedCrossRefGoogle Scholar
  18. 18.
    Habermalz HJ, Fischer JJ. Radiation therapy of malignant melanoma. Experience with high individual treatment doses. Cancer. 1976; 38: 2258–2262.PubMedCrossRefGoogle Scholar
  19. 19.
    Hornsey S. The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients. Br J Radiol. 1978; 51: 905–909.PubMedCrossRefGoogle Scholar
  20. 20.
    Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982; 8: 1131–1134.PubMedGoogle Scholar
  21. 21.
    Johanson CR, Harwood AR, Cummings BJ, et al. 0-7-21 radiotherapy in nodular melanoma. Cancer. 1983; 51: 226–232.PubMedCrossRefGoogle Scholar
  22. 22.
    Overgaard J, Overgaard M, Hansen PV, et al. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol. 1986; 5: 183–192.PubMedCrossRefGoogle Scholar
  23. 23.
    Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology. 1987; 164: 607–610.PubMedGoogle Scholar
  24. 24.
    Rounsaville MC, Cantril St, Fontanesi J, et al. Radiotherapy in the management of cutaneous melanoma. Effect of time, dose, and fractionation. Front Radiat Ther Oncol 1988; 22: 62–78.PubMedGoogle Scholar
  25. 25.
    Braun-Falco O, Lukacs S, Schoefinius HH. Zur Behandlung der melanosis circumscripta praecancerosa dubreuilh. Hautarzt. 1975; 26: 207–210.PubMedGoogle Scholar
  26. 26.
    Storck H. Treatment of melanotic freckles by radiotherapy. J Dermatol Surg Oncol. 1977; 3: 292–294.Google Scholar
  27. 27.
    Hauss H, Proppe A, Goldschmidt H. Radiotherapy of Lentigo maligna and Bowen’s disease. In: Gold-schmidt H, ed. Physical Modalities in Dermatologie therapy. New York, NY: Springer-Verlag; 1978: 122–129.Google Scholar
  28. 28.
    Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1982; 6: 310–316.PubMedCrossRefGoogle Scholar
  29. 29.
    Panizzon R. Radiotherapy of lentigo maligna and lentigo maligna-melanoma. In: Orfanos CE, Stadler R, Gollnick H, eds. Dermatology in Five Continents. Berlin: Springer-Verlag; 1988: 930–932.Google Scholar
  30. 30.
    Kopf AF, Bart RS, Gladstein AH. Treatment of melanotic freckle with x-rays. Arch Dermatol. 1976; 112: 801–807.PubMedCrossRefGoogle Scholar
  31. 31.
    Harwood AR, Cummings BJ. Radiotherapy for malignant melanoma: a reappraisal. Cancer Treat Rev. 1981; 8: 271–282.PubMedCrossRefGoogle Scholar
  32. 32.
    Haarwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1982; 6: 310–316.CrossRefGoogle Scholar
  33. 33.
    Salmi R, Holsti P. Effects of roentgen irradiation on human melanoma metastases in the skin. Acta Oncol. 1987; 26: 37–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1991

Authors and Affiliations

  • Renato G. Panizzon

There are no affiliations available

Personalised recommendations